Skip to main content

Kurma Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

85
Companies
$2.6B
Total invested
$30.5M
Avg. check
27
Industries
Biotechnology 14Health Care 12Medical 8Pharmaceutical 5Life Science 4Therapeutics 3+21 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 85
RougeTx
October 2026

RougeTx is a biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction.

Naarden$58.0M Series A
Nuclidium
May 2026

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Health Care · Basel$33.6M Series B
Tacalyx
April 2026

Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.

Biotechnology · Berlin$12.9M Seed
Laigo Bio
March 2026

Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.

Biotechnology · Utrecht$6.4M Seed
Charles.co
March 2026

Charles helps men regain control over their daily health concerns by starting with their personal health.

Fitness · Paris$297K Secondary Market
Step Pharma
February 2026

Step Pharma is a biotechnology company.

Biotechnology · Paris$2.9M Grant
Alveus Therapeutics
January 2026

Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.

Biotechnology · Philadelphia$197.0M Series A
DAMAE Medical
November 2025

DAMAE Medical develops an innovative imaging process for quick and non-invasive skin cancer detection.

Biotechnology · Paris$17.4M Series B
Adcytherix
October 2025

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

Biotechnology · Marseille$122.4M Series A
Sunrise
September 2025

We are a virtual sleep clinic, using our own 3-gram sensor to diagnose sleep with gold standard quality.

Health Care · Brussels$29.4M Venture - Series Unknown
Synendos Therapeutics
September 2025

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders.

Health Care · AllschwilGrant
Minoryx Therapeutics
July 2025

Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.

Biotechnology · Barcelona$31.5M Grant
EvlaBio
July 2025

EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.

Biotechnology · Zürich$24.6M Seed
Elkedonia
June 2025

Elkedonia is a biotech company dedicated to transforming antidepressant therapy.

Biotechnology · Strasbourg$12.9M Seed
Nuevocor
May 2025

Nuevocor operates as a preclinical-stage biotech company.

Biopharma · Singapore$45.0M Series B
DeepUll
April 2025

DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.

Biotechnology · Barcelona$56.9M Series C
Poppins
April 2025

We digitize music therapy into engaging products for accessible technologies.

EdTech · Paris$5.7M Venture - Series Unknown
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
Brink Therapeutics
April 2025

Brink Therapeutics is a Biotechnology Research firm conducting cell therapy research using reprogrammed recombinases.

Biotechnology · Paris$4.0M Seed
Hopia
January 2025

Optimized resource planning solution for healthcare institutions

Health Care · Paris$3.7M Seed
Coave Therapeutics
January 2025

Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.

Biotechnology · Paris$32.9M Series A
Omnidoc
December 2024

Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.

Collaboration · Paris$6.3M Venture - Series Unknown
Meiogenix
December 2024

Meiogenix is a biotechnology company that develops breeding technologies.

Biotechnology · ParisSeries A
Raidium
November 2024

Radiology augmented GPT to tackle the complexity of precision medicine

Artificial Intelligence (AI) · Paris$16.9M Seed

Where Kurma Partners invests

Biotechnology14
Health Care12
Medical8
Pharmaceutical5
Life Science4
Therapeutics3

About Kurma Partners's portfolio

How many companies has Kurma Partners invested in?▸

Kurma Partners has invested in 85 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Kurma Partners invest in?▸

Kurma Partners's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Life Science. The firm invests across 27 different industry categories.

What is Kurma Partners's largest investment?▸

Among tracked funding rounds, Alveus Therapeutics received $197.0M in a Series A round. Kurma Partners's total known invested capital is $2.6B.

What is the average investment size for Kurma Partners?▸

Kurma Partners's average investment size is $30.5M across its portfolio of 85 companies.

What are Kurma Partners's most recent investments?▸

Recent Kurma Partners portfolio additions include RougeTx, Nuclidium, Tacalyx, Laigo Bio, Charles.co. These companies were founded in 2020 or later.

Reach the founders behind these 85 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →